Webinars & Presentations Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Presentation

Watch this video to learn about:

  • How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing.
  • The MaxCyte GTx™–a clinically-validated electroporation platform optimized for cell therapy manufacturing.
  • How to address key risk factors during the cell therapy manufacturing process, such as process variability, complexity, and product yield.
  • The importance of robust, expert technical and regulatory support in enhancing risk mitigation.

This video was broadcasted on Cell and Gene Therapy Insights on August 30, 2023.

Watch the presentation

Download the poster

Presenter

Headshot of Andrew Mancini

Andrew Mancini

Senior Field Applications Scientist at MaxCyte

Andrew is a Senior Field Application Scientist at MaxCyte specializing in supporting MaxCyte’s partners in developing processes for cGMP-compliant manufacturing of cell therapies. Prior to his time at MaxCyte, Andrew completed his PhD in biomedical sciences at the University of California, San Francisco, and a postdoc in the Advanced Cell Engineering lab at Genentech.